Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses - PubMed (original) (raw)
Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses
Hiroshi Tsuda et al. Clin Cancer Res. 2005.
Abstract
Purpose: Patients with ovarian clear cell adenocarcinoma generally have a poor response to combination chemotherapy and have overall poorer prognosis than patients with other histologic types of ovarian cancer. Genetic changes in this group of cancer have not been thoroughly explored. Identification of these changes may provide us new therapeutic targets to treat this disease.
Experimental design: Genomic and expression array analyses were applied on 30 clear cell ovarian cancer cases and 19 serous cases using a 10,816-element cDNA microarray platform. Further validation and clinical correlation studies were done on differentially expressed genes that are related to chemoresistance.
Results: Based on array analyses, 12 genes showed a significant increase in DNA and mRNA copy number and 5 genes showed a significant decrease in DNA and RNA copy number in clear cell tumors compared with those in the serous type. One of the genes was ABCF2, which belongs to the ATP-binding cassette gene superfamily and has been shown to amplify in other tumor types. Validation studies were done using real-time quantitative PCR and immunohistochemistry. The results showed significantly higher ABCF2 DNA and mRNA copy number and protein levels in clear cell cases compared with those in serous cases. Furthermore, in 20 clear cell cases with chemo-response data available, ABCF2 cytoplasmic staining was significantly higher in nonresponders than that in the responders (60.0% versus 28.5%; P = 0.0002).
Conclusions: These data suggest that ABCF2 protein may be a prognostic marker for ovarian clear cell ovarian adenocarcinoma.
Similar articles
- Differential expression of ABCF2 protein among different histologic types of epithelial ovarian cancer and in clear cell adenocarcinomas of different organs.
Nishimura S, Tsuda H, Ito K, Jobo T, Yaegashi N, Inoue T, Sudo T, Berkowitz RS, Mok SC. Nishimura S, et al. Hum Pathol. 2007 Jan;38(1):134-9. doi: 10.1016/j.humpath.2006.06.026. Epub 2006 Sep 25. Hum Pathol. 2007. PMID: 16996567 - Relationship between ABCF2 expression and response to chemotherapy or prognosis in clear cell adenocarcinoma of the ovary.
Tsuda H, Ito K, Yaegashi N, Hirasawa A, Sudo T, Kita T, Terai Y, Kigawa J, Sugiyama T, Aoki D. Tsuda H, et al. Int J Gynecol Cancer. 2010 Jul;20(5):794-7. doi: 10.1111/igc.0b013e3181a835fc. Int J Gynecol Cancer. 2010. PMID: 20973270 - Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform.
Tsuda H, Birrer MJ, Ito YM, Ohashi Y, Lin M, Lee C, Wong WH, Rao PH, Lau CC, Berkowitz RS, Wong KK, Mok SC. Tsuda H, et al. Cancer Genet Cytogenet. 2004 Dec;155(2):97-107. doi: 10.1016/j.cancergencyto.2004.03.002. Cancer Genet Cytogenet. 2004. PMID: 15571795 - [Gene expression profiling of human ovarian epithelial tumors by digo nucleotide microarray].
Konno R. Konno R. Hum Cell. 2001 Dec;14(4):261-6. Hum Cell. 2001. PMID: 11925926 Review. Japanese. - Microarray-based gene expression studies in ovarian cancer.
Chon HS, Lancaster JM. Chon HS, et al. Cancer Control. 2011 Jan;18(1):8-15. doi: 10.1177/107327481101800102. Cancer Control. 2011. PMID: 21273975 Review.
Cited by
- Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.
Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, Tsuda H, Suzuki M, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Sugiyama T. Takano M, et al. Br J Cancer. 2006 May 22;94(10):1369-74. doi: 10.1038/sj.bjc.6603116. Br J Cancer. 2006. PMID: 16641903 Free PMC article. - Ovarian cancer stem cell markers: prognostic and therapeutic implications.
Burgos-Ojeda D, Rueda BR, Buckanovich RJ. Burgos-Ojeda D, et al. Cancer Lett. 2012 Sep 1;322(1):1-7. doi: 10.1016/j.canlet.2012.02.002. Epub 2012 Feb 11. Cancer Lett. 2012. PMID: 22334034 Free PMC article. Review. - ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells.
Bao L, Wu J, Dodson M, Rojo de la Vega EM, Ning Y, Zhang Z, Yao M, Zhang DD, Xu C, Yi X. Bao L, et al. Mol Carcinog. 2017 Jun;56(6):1543-1553. doi: 10.1002/mc.22615. Epub 2017 May 2. Mol Carcinog. 2017. PMID: 28112439 Free PMC article. - ADAM9 is over-expressed in human ovarian clear cell carcinomas and suppresses cisplatin-induced cell death.
Ueno M, Shiomi T, Mochizuki S, Chijiiwa M, Shimoda M, Kanai Y, Kataoka F, Hirasawa A, Susumu N, Aoki D, Okada Y. Ueno M, et al. Cancer Sci. 2018 Feb;109(2):471-482. doi: 10.1111/cas.13469. Cancer Sci. 2018. PMID: 29247567 Free PMC article. - Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.
Takano M, Sugiyama T, Yaegashi N, Suzuki M, Tsuda H, Sagae S, Udagawa Y, Kuzuya K, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Kikuchi Y. Takano M, et al. Int J Clin Oncol. 2007 Aug;12(4):256-60. doi: 10.1007/s10147-007-0670-1. Epub 2007 Aug 20. Int J Clin Oncol. 2007. PMID: 17701003
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical